1. TAIYO HOLDINGS CO., LTD.
  2. Investor Relations
  3. IR News
  4. Notice Regarding Receiving Manufacturing and Marketing Approval for Additional Formulation, Madopar® L50 Combination Tablets for the Treatment of Parkinsonism
Notice Regarding Receiving Manufacturing and Marketing Approval for Additional Formulation, Madopar® L50 Combination Tablets for the Treatment of Parkinsonism
  • 2024/2/15
サブ-ナビゲーション
  • News Release
  • About Us
  • Group Companies
  • Business Domain
  • Products
  • Sustainability
  • Investor Relations
    • 現在位置:IR News
    • Management Policy
    • Corporate Governance
    • Disclosure Policy
    • IR Library
    • IR Calendar
    • Performance Overview
    • Financial Highlights
    • Return to Shareholders
    • Share Information
    • Outside Evaluations, etc.
    • Disclaimer
  • Our Challenges
  • Contact Us
  • Glossary
  • Terms of Use
  • About Personal Information
  • Social Media Policy
  • Cookie Policy
  • Cookie Preferences

Notice Regarding Receiving Manufacturing and Marketing Approval for Additional Formulation, Madopar® L50 Combination Tablets for the Treatment of Parkinsonism

  • 2024/2/15

VIEW IR NEWS

  • header-content
  • header-content
  • footer-content